Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 4;4(2):e000334. doi: 10.1136/bmjno-2022-000334

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Secondary end point, Expanded Disability Status Scale (EDSS) data analyses for the intention-to-treat population. Kaplan-Meier plots of the time to sustained progression of disability among patients receiving Neuroaspis plp10 as compared with placebo. Neuroaspis plp10 reduced the risk of sustained progression of disability by 73% over 2 years (HR, 0.27; 95% CI: 0.09 to 0.83). The cumulative probability of progression was 18.8% in the Neuroaspis plp10 and 47.4% in the placebo group.